HGH Fragment 176-191 (Human Growth Hormone C-terminal Fragment, AOD-9401 parent)

HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 of human growth hormone — the C-terminal 16-amino-acid segment of the full 191-amino-acid GH molecule. It is the parent compound that AOD-9604 was engineered from; AOD-9604 adds a tyrosine residue at the N-terminus for improved chemical stability, otherwise the two compounds are structurally identical and target the same biology.

The compound is widely sold by research-peptide vendors for community fat-loss use, often as a less-expensive alternative to AOD-9604. The research-grade product quality varies substantially across vendors; identity and purity verification matters more for HGH Fragment 176-191 than for many peptides because the molecule is structurally simple enough that mis-synthesized or incomplete-purity material can present as legitimate product.

Through the 1980s and 1990s, researchers investigating the structural basis of growth hormone's metabolic effects identified that different regions of the GH molecule mediated different downstream effects. The C-terminal region — specifically residues 176-191 — was identified as responsible for the lipolytic (fat-mobilizing) and antilipogenic activity of GH, while the IGF-1 elevation, growth-promoting effects, and insulin-antagonizing effects mapped to other regions of the molecule.

This structure-function mapping created an attractive pharmaceutical hypothesis: a synthetic peptide corresponding to just the fat-loss-relevant region could theoretically deliver weight-loss benefits without the unfavorable systemic effects of administering whole GH. Multiple research groups and pharmaceutical programs pursued this in the 1990s-2000s. AOD-9604 was the most advanced development product to emerge — a modified version with an added tyrosine residue at the N-terminus (Tyr-HGH 176-191) for improved manufacturing stability. AOD-9604 went through Phase 2b trials in obesity but failed to demonstrate superiority over placebo at the doses tested.

HGH Fragment 176-191 acts on growth-hormone-receptor-independent pathways to produce its lipolytic effects:

• Stimulates lipolysis in adipocytes — increases breakdown of triglycerides stored in fat cells, mobilizing fatty acids into circulation.
• Inhibits lipogenesis — reduces synthesis of new triglycerides in adipose tissue, shifting the lipid balance toward net fat reduction.
• Preferential visceral fat targeting — animal models show greater effects on visceral adipose tissue than subcutaneous fat, similar to full GH but without the broader metabolic consequences.
• Does not activate GH receptors at typical doses — this is the key mechanistic distinction from full GH. The fragment doesn't produce IGF-1 elevation, doesn't stimulate growth, doesn't drive insulin resistance, and doesn't carry the cardiac and arthralgia effects associated with chronic GH administration.

The mechanistic story is genuinely interesting: a small peptide fragment that captures the metabolic benefit of GH while losing the side effects. The translation from animal models to human clinical efficacy at acceptable doses has been substantially less straightforward than the mechanism suggests.

HGH Fragment 176-191 has a short plasma half-life (minutes to ~30 minutes), reflecting its small peptide size and rapid proteolytic clearance. Research-peptide community protocols typically use multiple-times-daily subcutaneous injection patterns to maintain plasma exposure. The compound has no oral bioavailability — degraded by gastric and intestinal proteases.

The peer-reviewed literature on HGH Fragment 176-191 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Research-peptide community protocols use subcutaneous injection in divided daily doses (typically 250-500 mcg per dose, 2-3 times daily), often administered fasted or pre-cardio to align with the lipolytic mechanism. No FDA-approved protocol exists for HGH Fragment 176-191 in any clinical context. The AOD-9604 Phase 2b program used 1 mg daily; the unmodified fragment is often used at proportionally similar total daily doses divided across multiple administrations.

HGH Fragment 176-191 is the parent compound to AOD-9604 and shares essentially the same mechanism, clinical-development arc, and honest framing. The structural insight that a small C-terminal GH fragment captures lipolytic activity without the broader metabolic effects of full GH is genuinely interesting biology; the translation to clinically meaningful human weight loss at acceptable doses has been substantially less successful than the mechanism suggested. The AOD-9604 Phase 2b failure in obesity is the most-important calibration point — if the modified, stability-improved version couldn't demonstrate superiority over placebo, the unmodified parent compound is unlikely to outperform it.

For bodybuilding-community use during cutting phases, the compound is widely sold and reasonably tolerated; the anecdotal effect reports likely benefit from being combined with caloric restriction and resistance training, where any modest lipolytic enhancement contributes to overall body-composition outcomes. For users targeting substantial weight loss, the GLP-1 receptor agonist class (semaglutide, tirzepatide, emerging retatrutide) produces dramatically larger and more reliable effects with stronger evidence support. For the broader "metabolic rate elevation" story — the output-side intervention space that GLP-1s don't address — the emerging HU6 controlled mitochondrial uncoupler represents the more promising forward-looking candidate. See our Best Peptides for Weight Loss 2026 ranking for the broader class comparison.